Evolution of Monovisc & Cingal
Over the past decade, Monovisc has become one of the most widely used hyaluronic acid injections worldwide—over 3 million injections delivered across multiple joints. There is strong reason for this.
There are many HA option available these days, with many new optoins coming to market. I often hear feedback that certain new ones are working great, but this after only 2 months…and even saline would offer a decent couple months by providing a ‘wash out’ effect. But how can you trust you’re givng the patient the best long term treatment. I don’t mean from just 1 injection, but it’s more about as you build up multiple injectoins with a patient over years. That is where the true differnces lie and I appreacite, it’s very hard to monitor those differences. Being data driven with evidence that is also backed by robust science provides the best way to forward in the sometimes murkey world of injection therpies.
Monovoisc has 88mg of and optimally crosslinked HA, also optimised is the molecular weight, and is derieved from non-animal sourcing. With minimal adverse events as low as 2%, the long term use of Monovisc is tghe safest and most proven of any option.
It’s the foundation of our education and support programmes for clinicians to relay to patients – trusted, evidence-backed, and easy to integrate into an MSK practice as a multi-joint single injection option.
But as patients demand more, we learn more about osteoarthritis and it’s complexities, inflammation becomes a major part of the clinician to patient conversation, Cingal was developed as the natural next step.
Cingal builds on Monovisc’s success by combining the same HA base with a fast-acting, targeted corticosteroid, offering:
-
Rapid pain relief, taking effect from 48 hrs
-
Sustained joint support from nearly 20 years of heritage from Monovisc
-
Clinically proven outcomes across pain, function, and time to next intervention (92% responder index, 72% pain reduction – Hangody et al.)
To truly educate your patients on the effects of HA and the role of inflammation and the ongoing biology, both Monovisc & Cingal fit together perfectly. No two HA’s are the same, most do not have level 1 data and no others tell a such a compelling and trusted pathway for OA pain management as Monovisc and Cingal do.
For clinics that are joined up in this way of thinking, we support you with package pricing, alongside the shared education tools, and any further guidance on how to discuss both options with patients.
If you’d like to review the clinical data or have a more indepth chat about how this offering both creates a compelling discussion please do get intouch